IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/30/2026 11:45 PDT] IceCure Medical Ltd (NASDAQ:ICCM), Down By 100% ($0.38) From $0.375 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/30/2026 07:07 PDT] ICCM Expected to Trade Down After Bearish Patterns Develop
• [03/26/2026 10:29 PDT] IceCure Medical Ltd (NASDAQ:ICCM), Down By 100% ($0.6) From $0.6 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/19/2026 07:04 PDT] ICCM Expected to Trade Down After Bearish Patterns Develop
• [02/06/2026 07:22 PST] ICCM Expected to Trade Down After Bearish Patterns Develop